All the sessions from Transform 2021 are available on-demand now. Watch now.


Today, the Federal Trade Commission issued a final order against MelApp for a deceptive claim that it could diagnose or assess a person’s risk of melanoma through its mobile app.

The startup will be fined $17,963 and will be barred from asserting that its app is capable of detecting or diagnosing potential moles or skin lesions as cancerous unless they can support their claims with legitimate scientific evidence.

MelApp first received attention when it launched in 2011 as an early melanoma detection system. The $1.99 mobile app allowed users to take a picture of a suspect mole and have the image analyzed against a database of images for risk assessment. The app was created by Health Discovery Corporation and leverages John Hopkins’ image database to diagnose users.

In February the FTC took action against both MelApp and competitor app Mole Detective for claiming to be able to accurately assess a potential melanoma based on a photograph and a few questions.

The fine shows how difficult it will be for future mobile entrepreneurs to launch health apps that go beyond basic fitness and heart rate monitoring.

VentureBeat

VentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative technology and transact. Our site delivers essential information on data technologies and strategies to guide you as you lead your organizations. We invite you to become a member of our community, to access:
  • up-to-date information on the subjects of interest to you
  • our newsletters
  • gated thought-leader content and discounted access to our prized events, such as Transform 2021: Learn More
  • networking features, and more
Become a member